Hsbc Holdings PLC Makes New $275 Million Investment in Danaher Corporation $DHR

Hsbc Holdings PLC bought a new stake in Danaher Corporation (NYSE:DHR) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 1,443,380 shares of the conglomerate’s stock, valued at approximately $274,998,000.

Other hedge funds have also bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Danaher in the 2nd quarter worth about $10,492,520,000. State Street Corp raised its holdings in Danaher by 1.7% during the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after acquiring an additional 472,608 shares during the period. Capital International Investors boosted its stake in Danaher by 8.9% in the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after purchasing an additional 1,487,768 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Danaher by 9.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock valued at $3,656,595,000 after acquiring an additional 1,334,221 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of Danaher by 11.2% during the 4th quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after purchasing an additional 1,517,904 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DHR has been the subject of several recent analyst reports. TD Cowen cut their price objective on Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Stifel Nicolaus lowered their target price on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Citigroup started coverage on shares of Danaher in a report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price target for the company. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 target price on shares of Danaher in a research note on Wednesday, July 22nd. Finally, HSBC reduced their price target on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $228.91.

Danaher Stock Up 0.3%

DHR opened at $215.78 on Wednesday. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The firm’s 50 day simple moving average is $197.17 and its two-hundred day simple moving average is $192.36. The company has a market capitalization of $151.69 billion, a PE ratio of 38.33, a PEG ratio of 2.68 and a beta of 0.78. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. During the same quarter in the prior year, the business posted $0.77 earnings per share. The business’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, equities analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.